Document:

<PAGE>

                                                                   Exhibit 10.49

                         REGISTRATION RIGHTS AGREEMENT

     This Agreement dated as of September 26, 1996 is entered into by and among
Corange International Limited, (the "Purchaser") and Ontogeny, Inc., a Delaware
corporation (the "Company").

     WHEREAS, the Company and the Purchasers desire to provide for certain
arrangements with respect to the registration of shares of capital stock of the
Company under the Securities Act of 1933;

     NOW, THEREFORE, in consideration of the mutual promises and covenants
contained in this Agreement, the parties hereto agree as follows:

1.  Registration Rights.

    1.1 Certain Definitions. As used in this Agreement, the following terms
shall have the following respective meanings:

          "Commission" means the Securities and Exchange Commission, or any
other Federal agency at the time administering the Securities Act.

          "Common Stock" means the common stock, $.01 par value per share, of
the Company.

          "Exchange Act" means the Securities Exchange Act of 1934, as amended,
or any similar Federal statute, and the rules and regulations of the Commission
issued under such Act, as they each may, from time to time, be in effect.

          "Registration Statement" means a registration statement filed by the
Company with the Commission for a public offering and sale of Common Stock
(other than a registration statement on Form S-8 or Form S-4, or their
successors, or any other form for a similar limited purpose, any registration
statement covering only securities proposed to be issued in exchange for
securities or assets of another corporation or any registration statement
covering only securities to be sold for the account of stockholders of the
Company).

          "Registration Expenses" means the expenses described in Section 1.5.

          "Registrable Shares" means (i) the shares of Common Stock issued or
issuable upon conversion of the Shares, (ii) any other shares of Common Stock
issued in respect of such shares (because of stock splits, stock dividends,
reclassifications, recapitalizations, or similar events); provided, however,
that shares of Common Stock which are Registrable Shares shall cease to be
Registrable Shares (i) upon any sale pursuant to a Registration Statement or
Rule 144 under the Securities Act or (ii) upon any sale in any manner to a
person or entity which, by virtue of Section 2 of this Agreement, is not
entitled to the rights provided by this Agreement.  Wherever reference is made
in this Agreement to a request or consent of holders of a certain percentage of
Registrable Shares, the determination of such percentage shall include shares of
Common Stock issuable upon conversion of the Shares even if such conversion has
not yet been effected.
<PAGE>

          "Securities Act" means the Securities Act of 1933, as amended, or any
similar Federal statute, and the rules and regulations of the Commission issued
under such Act, as they each may, from time to time, be in effect.

          "Shares" means the shares of Series D Convertible Preferred Stock
issued pursuant to the Series D Preferred Stock Purchase Agreement of even date
herewith by and between the Company and the Purchaser and any shares of
preferred stock issued to Purchaser pursuant to Section 4.1 of the Research and
Commercialization Agreement of even date herewith between the Company and the
Purchaser.

          "Stockholders" means the Purchaser and any persons or entities to whom
the rights granted under this Agreement are transferred by Purchaser, pursuant
to Section 2 hereof.

    1.2 Required Registrations.

        (a) At any time after the Company becomes eligible to file a
Registration Statement on Form S-3 (or any successor form relating to secondary
offerings), a Stockholder or Stockholders may request the Company, in writing,
to effect the registration on Form S-3 (or such successor form), of Registrable
Shares having an aggregate offering price of at least $1,000,000 (based on the
then current public market price). Upon receipt of any such request, the Company
shall promptly give written notice of such proposed registration to all
Stockholders. Such Stockholders shall have the right, by giving written notice
to the Company within 30 days after the Company provides its notice, to elect to
have included in such registration such of their Registrable Shares as such
Stockholders may request in such notice of election; provided that if the
underwriter (if any) managing the offering determines that, because of marketing
factors, all of the Registrable Shares requested to be registered by all
Stockholders may not be included in the offering, then all Stockholders who have
requested registration shall participate in the registration pro rata based upon
their total ownership of shares of Common Stock (giving effect to the conversion
into Common Stock of all securities convertible thereinto). Thereupon, the
Company shall, as expeditiously as possible, use its best efforts to effect the
registration on Form S-3 (or such successor form) of all Registrable Shares
which the Company has been requested to so register.

        (b) The Company shall not be required to effect more than three
registrations pursuant to paragraph (a) above.

        (c) If at the time of any request to register Registrable Shares
pursuant to this Section 1.2, the Company is engaged or has fixed plans to
engage within 30 days of the time of the request in a registered public offering
as to which the Stockholders may include Registrable Shares pursuant to Section
1.3 or is engaged in any other activity which, in the good faith determination
of the Company's Board of Directors, would be adversely affected by the
requested registration to the material detriment of the Company, then the
Company may at its option direct that such request be delayed for a period not
in excess of six months from the effective date of such offering or the date of
commencement of such other material activity, as the case may be, such right to
delay a request to be exercised by the Company not more than once in any two-
year period.

                                       2
<PAGE>

        (d) The Company shall not be required to register under this Section 1.2
any Registrable Shares then eligible for resale under Rule 144(k) under the
Securities Act.

   1.3  Incidental Registration.

        (a) Whenever the Company proposes to file a Registration Statement
(other than pursuant to Section 1.2) at any time and from time to time, it will,
prior to such filing, give written notice to all Stockholders of its intention
to do so and, upon the written request of a Stockholder or Stockholders given
within 20 days after the Company provides such notice (which request shall state
the intended method of disposition of such Registrable Shares), the Company
shall use its best efforts to cause all Registrable Shares which the Company has
been requested by such Stockholder or Stockholders to register to be registered
under the Securities Act to the extent necessary to permit their sale or other
disposition in accordance with the intended methods of distribution specified in
the request of such Stockholder or Stockholders; provided that the Company shall
have the right to postpone or withdraw any registration effected pursuant to
this Section 1.3 without obligation to any Stockholder.

        (b) In connection with any registration under this Section 1.3 involving
an underwriting, the Company shall not be required to include (i) any
Registrable Shares in such registration unless the holders thereof accept the
terms of the underwriting as agreed upon between the Company and the
underwriters selected by it (provided that such terms must be consistent with
this Agreement), or (ii) except in the Company's initial public offering of
Common Stock or any Registration Statement filed by the Company with the
Commission within 24 months after the closing of such initial public offering,
any Registrable Shares then eligible for resale under Rule 144(k) under the
Securities Act. If in the opinion of the managing underwriter it is appropriate
because of marketing factors to limit the number of Registrable Shares to be
included in the offering, then the Company shall be required to include in the
registration only that number of Registrable Shares, if any, which the managing
underwriter believes should be included therein. If the number of Registrable
Shares to be included in the offering in accordance with the foregoing is less
than the total number of shares which the holders of Registrable Shares have
requested to be included, then the holders of Registrable Shares who have
requested registration and other holders of securities entitled to include them
in such registration shall participate in the registration pro rata based upon
their total ownership of shares of Common Stock (giving effect to the conversion
into Common Stock of all securities convertible thereinto). If any holder would
thus be entitled to include more securities than such holder requested to be
registered, the excess shall be allocated among other requesting holders pro
rata in the manner described in this paragraph.

   1.4  Registration Procedures.  If and whenever the Company is required by the
provisions of this Agreement to use its best efforts to effect the registration
of any of the Registrable Shares under the Securities Act, the Company shall:

        (a) file with the Commission a Registration Statement with respect to
such Registrable Shares and use its best efforts to cause that Registration
Statement to become and remain effective;

                                       3
<PAGE>

        (b) as expeditiously as possible prepare and file with the Commission
any amendments and supplements to the Registration Statement and the prospectus
included in the Registration Statement as may be necessary to keep the
Registration Statement effective, in the case of a firm commitment underwritten
public offering, until each underwriter has completed the distribution of all
securities purchased by it and, in the case of any other offering, until the
earlier of the sale of all Registrable Shares covered thereby or 120 days after
the effective date thereof;

        (c) as expeditiously as possible furnish to each selling Stockholder
such reasonable numbers of copies of the prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such
other documents as the selling Stockholder may reasonably request in order to
facilitate the public sale or other disposition of the Registrable Shares owned
by the selling Stockholder; and

        (d) as expeditiously as possible use its best efforts to register or
qualify the Registrable Shares covered by the Registration Statement under the
securities or Blue Sky laws of such states as the selling Stockholders shall
reasonably request, and do any and all other acts and things that may be
necessary or desirable to enable the selling Stockholders to consummate the
public sale or other disposition in such states of the Registrable Shares owned
by the selling Stockholder; provided, however, that the Company shall not be
required in connection with this paragraph (d) to qualify as a foreign
corporation or execute a general consent to service of process in any
jurisdiction.

     If the Company has delivered preliminary or final prospectuses to the
selling Stockholders and after having done so the prospectus is amended to
comply with the requirements of the Securities Act, the Company shall promptly
notify the selling Stockholders and, if requested, the selling Stockholders
shall immediately cease making offers of Registrable Shares and return all
prospectuses to the Company.  The Company shall promptly provide the selling
Stockholders with revised prospectuses and, following receipt of the revised
prospectuses, the selling Stockholders shall be free to resume making offers of
the Registrable Shares.

   1.5 Allocation of Expenses. The Company will pay all Registration Expenses of
all registrations under this Agreement; provided, however, that if a
registration under Section 1.2 is withdrawn at the request of the Stockholders
requesting such registration (other than as a result of information concerning
the business or financial condition of the Company which is made known to the
Stockholders after the date on which such registration was requested) and if the
requesting Stockholders elect not to have such registration counted as a
registration requested under Section 1.2, the requesting Stockholders shall pay
the Registration Expenses of such registration pro rata in accordance with the
number of their Registrable Shares included in such registration. For purposes
of this Section 1.5, the term "Registration Expenses" shall mean all expenses
incurred by the Company in complying with this Agreement, including, without
limitation, all registration and filing fees, exchange listing fees, printing
expenses, fees and expenses of counsel for the Company and the fees and expenses
of one counsel selected by the selling Stockholders to represent the selling
Stockholders, state Blue Sky fees and expenses, and the expense of any special
audits incident to or required by any such registration, but

                                       4
<PAGE>

excluding underwriting discounts, selling commissions and the fees and expenses
of selling Stockholders' own counsel (other than the counsel selected to
represent all selling Stockholders).

1.6  Indemnification and Contribution.

        (a) In the event of any registration of any of the Registrable Shares
under the Securities Act pursuant to this Agreement, the Company will indemnify
and hold harmless the seller of such Registrable Shares, each underwriter of
such Registrable Shares, and each other person, if any, who controls such seller
or underwriter within the meaning of the Securities Act or the Exchange Act
against any losses, claims, damages or liabilities, joint or several, to which
such seller, underwriter or controlling person may become subject under the
Securities Act, the Exchange Act, state securities or Blue Sky laws or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or are based upon any untrue statement or alleged
untrue statement of any material fact contained in any Registration Statement
under which such Registrable Shares were registered under the Securities Act,
any preliminary prospectus or final prospectus contained in the Registration
Statement, or any amendment or supplement to such Registration Statement, or
arise out of or are based upon the omission or alleged omission to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading; and the Company will reimburse such seller, underwriter
and each such controlling person for any legal or any other expenses reasonably
incurred by such seller, underwriter or controlling person in connection with
investigating or defending any such loss, claim, damage, liability or action;
provided, however, that the Company will not be liable in any such case to the
extent that any such loss, claim, damage or liability arises out of or is based
upon any untrue statement or omission made in such Registration Statement,
preliminary prospectus or final prospectus, or any such amendment or supplement,
in reliance upon and in conformity with information furnished to the Company, in
writing, by or on behalf of such seller, underwriter or controlling person
specifically for use in the preparation thereof.

        (b) In the event of any registration of any of the Registrable Shares
under the Securities Act pursuant to this Agreement, each seller of Registrable
Shares, severally and not jointly, will indemnify and hold harmless the Company,
each of its directors and officers and each underwriter (if any) and each
person, if any, who controls the Company or any such underwriter within the
meaning of the Securities Act or the Exchange Act, against any losses, claims,
damages or liabilities, joint or several, to which the Company, such directors
and officers, underwriter or controlling person may become subject under the
Securities Act, Exchange Act, state securities or Blue Sky laws or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any untrue statement or alleged untrue
statement of a material fact contained in any Registration Statement under which
such Registrable Shares were registered under the Securities Act, any
preliminary prospectus or final prospectus contained in the Registration
Statement, or any amendment or supplement to the Registration Statement, or
arise out of or are based upon any omission or alleged omission to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading, if the statement or omission was made in reliance upon
and in conformity with information relating to such seller furnished in writing
to the Company by or on behalf of such seller specifically for use in connection
with the preparation of such Registration Statement, prospectus, amendment or
supplement; provided, however, that the obligations of

                                       5
<PAGE>

each Stockholder hereunder shall be limited to an amount equal to the net
proceeds received by such Stockholder from Registrable Shares sold in connection
with such registration.

        (c) Each party entitled to indemnification under this Section 1.6 (the
"Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom; provided, that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or litigation, shall be
approved by the Indemnified Party (whose approval shall not be unreasonably
withheld); and, provided, further, that the failure of any Indemnified Party to
give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Section 1.6. The Indemnified Party may participate in
such defense at such party's expense; provided, however, that the Indemnifying
Party shall pay such expense if representation of such Indemnified Party by the
counsel retained by the Indemnifying Party would be inappropriate due to actual
or potential differing interests between the Indemnified Party and any other
party represented by such counsel in such proceeding. No Indemnifying Party, in
the defense of any such claim or litigation shall, except with the consent of
each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect of such claim or litigation, and no Indemnified Party shall
consent to entry of any judgment or settle such claim or litigation without the
prior written consent of the Indemnifying Party.

        (d) In order to provide for just and equitable contribution to joint
liability under the Securities Act in any case in which either (i) any holder of
Registrable Shares exercising rights under this Agreement, or any controlling
person of any such holder, makes a claim for indemnification pursuant to this
Section 1.6 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal
or the denial of the last right of appeal) that such indemnification may not be
enforced in such case notwithstanding the fact that this Section 1.6 provides
for indemnification in such case, or (ii) contribution under the Securities Act
may be required on the part of any such selling Stockholder or any such
controlling person in circumstances for which indemnification is provided under
this Section 1.6; then, in each such case, the Company and such Stockholder will
contribute to the aggregate losses, claims, damages or liabilities to which they
may be subject (after contribution from others) in such proportions so that such
holder is responsible for the portion represented by the percentage that the
public offering price of its Registrable Shares offered by the Registration
Statement bears to the public offering price of all securities offered by such
Registration Statement, and the Company is responsible for the remaining
portion; provided, however, that, in any such case, (A) no such holder will be
required to contribute any amount in excess of the net proceeds to it of all
Registrable Shares sold by it pursuant to such Registration Statement, and (B)
no person or entity guilty of fraudulent misrepresentation, within the meaning
of Section 11(f) of the Securities Act, shall be entitled to contribution from
any person or entity who is not guilty of such fraudulent misrepresentation.

   1.7 Indemnification with Respect to Underwritten Offering. In the event that
Registrable Shares are sold pursuant to a Registration Statement in an
underwritten offering

                                       6
<PAGE>

pursuant to Section 1.2, the Company agrees to enter into an underwriting
agreement containing customary representations and warranties with respect to
the business and operations of an issuer of the securities being registered and
customary covenants and agreements to be performed by such issuer, including
without limitation customary provisions with respect to indemnification by the
Company of the underwriters of such offering.

   1.8  Information by Holder.  Each Stockholder including Registrable Shares in
any registration shall furnish to the Company such information regarding such
Stockholder and the distribution proposed by such Stockholder as the Company may
reasonably request in writing and as shall be required in connection with any
registration, qualification or compliance referred to in this Agreement.

   1.9 "Stand-Off" Agreement. Each Stockholder, if requested by the Company and
the managing underwriter of an offering by the Company of Common Stock or other
securities of the Company pursuant to a Registration Statement, shall agree not
to sell publicly or otherwise transfer or dispose of any Registrable Shares or
other securities of the Company held by such Stockholder for a period of 180
days following the effective date of such Registration Statement; provided,
that:

        (a) such agreement shall only apply to the Registration Statement
covering the Company's initial public offering of Common Stock in an
underwritten offering; and

        (b)  all officers and directors of the Company shall enter into similar
agreements.

   1.10 Rule 144 Requirements. After the earliest of (i) the closing of the sale
of securities of the Company pursuant to a Registration Statement, (ii) the
registration by the Company of a class of securities under Section 12 of the
Exchange Act, or (iii) the issuance by the Company of an offering circular
pursuant to Regulation A under the Securities Act, the Company agrees to:

        (a) comply with the requirements of Rule 144(c) under the Securities Act
with respect to current public information about the Company;

        (b) use its best efforts to file with the Commission in a timely manner
all reports and other documents required of the Company under the Securities Act
and the Exchange Act (at any time after it has become subject to such reporting
requirements); and

        (c) furnish to any holder of Registrable Shares upon request (i) a
written statement by the Company as to its compliance with the requirements of
said Rule 144(c), and the reporting requirements of the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting
requirements), (ii) a copy of the most recent annual or quarterly report of the
Company, and (iii) such other reports and documents of the Company as such
holder may reasonably request to avail itself of any similar rule or regulation
of the Commission allowing it to sell any such securities without registration.

                                       7
<PAGE>

   1.11  Termination.  All of the Company's obligations to register Registrable
Shares under this Agreement shall terminate on the date seven years after the
closing of the Company's initial public offering of Common Stock pursuant to a
Registration Statement.

2.  Transfers of Rights.  This Agreement, and the rights and obligations of each
Purchaser hereunder, may be assigned by such Purchaser to any person or entity
to which at least 100,000 Shares are transferred by such Purchaser, and such
transferee shall be deemed a "Purchaser" for purposes of this Agreement;
provided that the transferee provides written notice of such assignment to the
Company and agrees to be bound hereby and provided further that the transferee
is not a competitor of the Company.

3.  General.

        (a) Notices. All notices, requests, consents, and other communications
under this Agreement shall be in writing and shall be delivered by hand or
mailed by first class certified or registered mail, return receipt requested,
postage prepaid:

     If to the Company, at 45 Moulton Street, Cambridge, Massachusetts 02138,
Attention: President, or at such other address or addresses as may have been
furnished in writing by the Company to the Purchaser, with a copy to Mark G.
Borden, Esq., Hale and Dorr, 60 State Street, Boston, Massachusetts 02109; or

     If to a Purchaser, at his or its address set forth in the Series D Purchase
Agreement, or at such other address or addresses as may have been furnished to
the Company in writing by such Purchaser.

        (b) Entire Agreement. This Agreement embodies the entire agreement and
understanding between the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and understandings relating to such
subject matter.

        (c) Amendments and Waivers. Any term of this Agreement may be amended
and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), with the
written consent of the Company and the holders of at least 66 2/3% of the then
outstanding Registrable Shares (including shares issued upon conversion
thereof). No waivers of or exceptions to any term, condition or provision of
this Agreement, in any one or more instances, shall be deemed to be, or
construed as, a further or continuing waiver of any such term, condition or
provision.

        (d) Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original, but all of which
shall be one and the same document.

        (e) Severability. The invalidity or unenforceability of any provision of
this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement.

        (f) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts.

                                       8
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have set their hands as of the date
first written above:

                              COMPANY:

                              ONTOGENY, INC.

                              /s/
                              ___________________________________

                              Dated: ____________________________

                              PURCHASER:

                              CORANGE INTERNATIONAL LIMITED

                              By: /s/
                                  _______________________________

                              By: _______________________________

                              Dated: ____________________________

                                       9<PAGE>

                                                                  Exhibit 10.50
                                                                  -------------

                  SCIENTIFIC ADVISORY AND COSULTING AGREEMENT
                  -------------------------------------------

     THIS AGREEMENT, effective as Of August 1, 1994, is by and between Douglas
A. Melton (the "Scientific Advisor"), and Ontogeny, Inc., a Delaware corporation
(the "Company").

     The parties agree as follows:

     1.   Term. The term of the Scientific Advisor's consulting arrangement
hereunder (the "Term") shall commence on the date hereof, and, unless sooner
terminated as provided in this Agreement, shall continue through July 31, 1999,
provided that the Term may be extended by mutual written agreement of the
parties subject to the prior written approval of the Institute. The Term shall
automatically terminate upon the death or permanent disability of the Scientific
Advisor.

     2.   Service as Scientific Advisor and Consultant.

          (a)  The Company shall retain Scientific Advisor as a consultant and
     Chairman of its Scientific Advisory Board, and Scientific Advisor shall
     serve the Company as a consultant and Chairman of its Scientific Advisory
     Board, upon the terms and conditions set forth in this Agreement.

          (b)  During the Term, Scientific Advisor shall render to the Company
     such consulting services in his fields of expertise and knowledge related
     to the business of the Company and at such times and places as the Company
     may from time to time reasonably request, including the strategic direction
     of the Company and future strategic decisions, recruitment and direction of
     key technical personnel, creation of competitive technology assets (such as
     patents and technology sharing agreements), and consultation with the
     Company's technical personnel, research sponsors and collaborators. In
     recognition to the Institution Rules (as defined below) the Company and the
     Consultant agree that the provision of services hereunder may involve the
     exchange of ideas but the consultant shall not direct or conduct research
     for or on behalf of the Company. The parties agree and acknowledge that
     such consulting services shall primarily be rendered at the Company's
     offices in Massachusetts.

          (c)  The Scientific Advisor shall devote, at the Company's request, up
to 20 full days or full-day equivalents to the performance of services hereunder
in each 12 month period (August 1 to July 31) during the Term. A "full-day
equivalent" shall mean eight (8) business hours. The Scientific Advisor shall
not, during the Term, devote any available consulting time to any other
commercial organization, provided, however, that the Scientific Advisor may
devote up to four days per annum to consulting for Gilead Sciences, Inc.

     3.   Certain Other Obligations.

          (a)  The Company recognizes that the Scientific Advisor's primary
     responsibility is to Harvard University and the Howard Hughes Medical
     Institute (the "Institute") (collectively, the "Institutions") and that the
     Scientific Advisor has entered into certain agreements with, and is subject
     to certain policies of, the Institutions relating to the ownership of
     intellectual property, conflicts of interest and similar matters (the
     "Institution Rules"), copies of
<PAGE>

     which has been provided to the Company. If any provisions of this Agreement
     are in conflict with the Institution Rules, the Institution Rules will
     govern and control to the extent of such conflict. The Scientific Advisor
     shall not disclose to the Company any information that (i) the Scientific
     Advisor is obligated to keep secret pursuant to a confidentiality agreement
     with the Institutions or any other third party or (ii) constitutes
     technology, inventions or other intellectual property of the Institutions
     or any other third party.

          (b)  The consulting work performed hereunder will not be conducted on
     time that is required to be devoted to the Institutions. The Scientific
     Advisor shall not use the funding, resources and/or facilities of the
     Institutions or any third party to perform consulting services hereunder
     and shall not perform such consulting services in any manner that would
     give the Institutions or any third party intellectual property rights or
     any other rights to the product of such services.

          (c)  The Scientific Advisor has disclosed, and will disclosure during
     the term of this Agreement, to the Chief Executive Officer of the Company
     any potential conflicts between this Agreement and other contracts binding
     the Scientific Advisor.

     4.   No Competition. Scientific Advisor agrees that, during the Term and
for one (1) year after the end of the Term, Scientific Advisor shall not,
directly or indirectly,

          (a)  as an individual proprietor, partner, stockholder, officer,
     employee, consultant, director, investor, lender or in any other capacity
     (other than as the holder of not more than one percent of the outstanding
     stock of a publicly held company), develop or sell (or assist any other
     person in developing or selling) products or services competitive with
     those developed or sold or planned to be developed or sold, by the Company
     during the Term; or

          (b)  directly or indirectly, solicit or induce any employee of the
     Company to leave the employ of the Company.

     However, the foregoing shall not affect Scientific Advisor's obligations
to, or research on behalf of, the Institute or the University, including,
without limitation, obligations or research of Scientific Advisor in connection
with a transfer by the Institute or the University of materials or intellectual
property developed in whole or in part by Scientific Advisor, or in connection
with research collaborations.

     5.   Compensation.

          (a)  In consideration for the services rendered by Scientific Advisor
     to the Company, the Company shall pay Scientific Advisor, during the Term,
     compensation as follows:

               (1)  a consulting fee of $30,000 per annum, payable in equal
          quarterly installments within 30 days after the end of each three-
          month period during the period from August 1 to July 31 of each year
          (a "Contract Year").

               (2)  a fee of $1,000 for each full day or full-day equivalent of
          consulting services performed hereunder.
<PAGE>

          (b)  In addition, the Scientific Advisor and the Company shall execute
     and deliver a Stock Restriction Agreement, upon terms mutually agreed upon,
     relating to the issuance of shares of Common Stock of the Company to the
     Scientific Advisor. It is agreed that at no time will Scientific Advisor's
     ownership interest in the Company (treating all options as exercised and
     all shares as vested) exceed 5% of the Company's outstanding equity.

          (c)  Scientific Advisor shall not be entitled to any compensation for
     his services or time devoted to the Company in his capacity as a member of
     the Board of Directors of the Company.

     6.   Expenses. The Company shall reimburse Scientific Advisor for his
reasonable out-of-pocket expenses incurred in the performance of his duties
hereunder upon compliance with reasonable administrative policies established
from time to time by the Company.

     7.   Confidentiality. The Scientific Advisor recognizes and acknowledges
that all technology, know-how, inventions and business plans communicated to,
learned of, developed or otherwise acquired by the Scientific Advisor in the
course of his services hereunder and not in the course of his activities as an
institute employee or University faculty member ("Confidential Information") are
valuable assets of the Company to be kept confidential and not disclose or use,
except in connection with the fulfillment of his consulting services for the
company under this Agreement, any Confidential Information of the Company.
"Confidential Information" shall not include, however, information placed in the
public domain through no fault of the Scientific Advisor; information disclosed
to the Scientific Advisor by a third party entitled to disclose it; information
already known to the Scientific Advisor prior to receipt thereof from the
company; or information that is independently developed by the Scientific
Advisor without reference to information provided by the Company and not in the
course of the performance of his services hereunder.

     8.   Representations of the Scientific Advisor. The Scientific Advisor
hereby represents that his current principal employer has received full
disclosure as to the Scientific Advisor's acting as a scientific advisor to the
Company and of the duties required of the Scientific Advisor under this
Agreement, and that such employer, if necessary, has consented to the Scientific
Advisor's execution of the Agreement and position as a scientific advisor for
the Company. The Scientific Advisor further represents that there are no binding
agreements to which he is a party or by which he is bound forbidding or
restricting his activities hereunder, except as disclosed to the Company. In
addition, subject to Section 21 below, the Scientific Advisor consents to being
named as a Scientific Advisor in various reports, brochures or other documents
produced by or on behalf of the Company, including any and all documents filed
with the Securities and Exchange Commission.

     9.   Assignment of Inventions.

          (a)  Subject to Section 9(b) below, the Scientific Advisor hereby
     assigns to the Company all his right, title and interest in and to all
     inventions, discoveries, data, technologies and improvements, whether or
     not patentable or copyrightable, relating to the business or planned
     business of the Company that are made, conceived or reduced to practice,
     alone or jointly with others, in the course of the performance of his
     services hereunder and not in the
<PAGE>

     course of his activities as an Institute employee or University faculty
     member (collectively, "Inventions"), and all patents, copyrights and other
     intellectual property rights relating thereto. The Scientific Advisor
     agrees to cooperate fully in the prosecution of any patent application
     relating to any such Invention, at the expense of the company, which
     cooperation shall include executing any necessary documents in connection
     therewith.

          (b)  The Company shall have no rights by reason of this Agreement in
     any invention, discovery, data, technology or improvement, whether or not
     patentable or copyrightable, which is developed as a result of a program of
     research financed, in whole or in part, by funds provided by or under the
     control of the Institute or the University.

          (c)  The Scientific Advisor shall promptly disclose to the Company all
     Inventions and will maintain adequate and current written records (in the
     form of notes, records, laboratory or research notebooks and as may be
     reasonably specified in advance by the Company) to document the conception
     and/or first actual reduction to practice of any Invention Such written
     records shall be available to and remain the sole property of the Company
     at all times.

     10.  Termination.

          (a)  This Agreement shall terminate upon (i) the death or permanent
     disability of the Scientific Advisor, (ii) the bankruptcy or cessation of
     operations of the Company, (iii) or upon termination for "Cause" (as
     defined below), or (iv) 30 days written notice given by either party to the
     other party. Upon such termination, the Company's obligations to the
     Scientific Advisor hereunder shall terminate, except for the payment of any
     consulting charges accrued and unpaid prior to the date of termination.

          (b)  The term "Cause,, means any of the following: (i) the Scientific
     Advisor's intentional or willful failure to perform his obligations under
     this Agreement in any material respect or the Scientific Advisor's material
     breach of any provision of this Agreement if such failure or breach shall
     continue for 30 days after notice in writing from the Chief Executive
     Officer of the Company specifying such failure or breach; (ii) the
     Scientific Advisor's conviction of a felony; or (iii) the Scientific
     Advisor's conviction of any lesser crime or offense committed in connection
     with the performance of his duties hereunder and involving moral turpitude.
     If the Company notifies the Scientific Advisor in writing that he is to be
     terminated for Cause, the Scientific Advisor shall have the right,
     exercisable within 10 days of receipt of such notice to submit the matter
     to the Board of Directors which will, within 20 day's after the Scientific
     Advisor's written request, meet and make a good faith determination whether
     Cause for termination exists, provided that in making such determination
     the Board of Directors shall give the Scientific Advisor an opportunity to
     appear at the Board meeting and be heard on the matter.

     11.  Survival of Provisions. The provisions of Sections 4.7, 9, 12 and 20
hereof shall survive the termination or expiration of this Agreement in
accordance with their terms.

     12.  Status. Scientific Advisor's relationship to the company shall be that
of an independent contractor and neither this Agreement nor the services to be
rendered hereunder shall for any purpose whatsoever or in any way or manner
create any employer-employee
<PAGE>

relationship between the parties. Scientific Advisor shall not be deemed an
agent for any purpose and shall have no authority to bind the Company in any
way, except as may be specifically authorized by the Company.

     13.  Assignability and Binding Effect. This Agreement shall inure to the
benefit of and shall be binding upon the Company and the Scientific Advisor and
their respective successors and permitted assigns, including any corporation or
entity with which, or into which, the Company may be merged or which may succeed
to its business or assets. The obligations of Scientific Advisor hereunder are
personal, and he may not assign or transfer any of his obligations or rights
hereunder.

     14.  Headings. The paragraph headings contained herein are included solely
for convenience of reference and shall not control or affect the meaning or
interpretation of any of the provisions of this Agreement.

     15.  Notices. Any notices or other communication hereunder by either party
shall be in writing and shall be deemed to have been duly given if delivered
personally to the other party or sent by registered or certified mail, return
receipt requested, to the other party at the following addresses:

          If to the Company:

               Ontogeny, Inc.
               One Kendall Square
               Building 600
               Cambridge, MA 02139

          If to the Scientific Advisor:

               Douglas A. Melton
               22 Slocum Road
               Lexington, MA 02173

or at such other address as such other party may designate in conformity with
the foregoing.

     16.  Entire Agreement. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement.

     17.  Delays or Omissions. No delay or omission by the Company in exercising
any right under this Agreement shall operate as a waiver of that or any other
right. A waiver or consent given by the Company on any one occasion shall be
effective only in that instance and shall not be construed as a bar or waiver of
any right on any other occasion.

     18.  Governing Law. This Agreement shall be governed by, and construed and
enforced in accordance with, the laws of the Commonwealth of Massachusetts
applicable to contracts made and to be performed therein, without giving effect
to the principles thereof relating to the conflict of laws.
<PAGE>

     19.  Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

     20.  Indemnity. The Company agrees, at its sole expense, to defend the
Institute and Scientific Advisor, and to indemnify and hold the Institute and
Scientific Advisor harmless from, any claims or suits by a third party against
the Institute or Scientific Advisor or any liabilities or judgments based
thereon, either arising from Scientific Advisor's performance of services for
the Company under this Agreement or arising from any Company products which
result from Scientific Advisor's performance of services under this Agreement,
provided that the Company shall have the right to control the defense and
settlement of such claims or suits.

     21.  Use of Names. The Company will not use Scientific Advisor's or the
Institute's or the University's name in any commercial advertisement or similar
material that is used to promote or sell products, unless the company obtains in
advance the written consent of the named party to such use, in addition, if the
Scientific Advisor's name is to be used for such purposes, the consent of the
Institute must also be obtained.

     22.  Consent. The Company and Scientific Advisor acknowledge that any
amendment of this Agreement (including, without limitation, any extension of
this Agreement or any change in the consideration to be provided to Scientific
Advisor with respect to services to be provided hereunder) or any departure from
the terms or conditions hereof with respect to Scientific Advisor's consulting
services for the Company is subject to the institute's prior written approval.

     IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as
of the day and year first above written.

                              ONTOGENY, INC.

                              By:  /s/ William Helman
                                 --------------------
                                   President

                              SCIENTIFIC ADVISOR

                              /s/ Douglas A. Melton
                              ---------------------
                                  Douglas A. Melton
<PAGE>

ONTOGENY, INC.
-------------------------------------------------------------------------------
November 12,1997

Dr. Douglas A. Melton
Dept. of Molecular & Cellular Biology
Harvard University
7 Divinity Avenue
Cambridge, MA 02138

Dear Doug,

Ontogeny would like to simplify your compensation (eliminating the need to bill
for the additional $1,000 per day of consulting services), by amending Section 5
as follows:

     Subparagraphs (a) and (b)
     ---------------------------
     Delete both subparagraphs, and insert "(a) pay to the Consultant an annual
     fee of $50,000 during the term hereof, payable in equal quarterly
     installments of $12,500 within thirty (30) days after the end of each
     three-month period from August 1 to July 31 of each year, and (b)".

     Subparagraph (c) becomes subparagraph (b).
     ----------------

All other terms of your Agreement with Ontogeny shall remain in full force and
effect.

If you are in agreement with the above, please sign the enclosed copy of this
letter and send us one copy for our files.

Very truly yours,

George A. Eldridge
Vice President, Finance             Acknowledged and Agreed,

                                    /s/ Douglas A. Melton
                                    -----------------------------------
                                    Douglas A. Melton
                                    Date:  /s/ 20 Nov. 97
                                          -----------------------------
<PAGE>

ONTOGENY, INC.
-------------------------------------------------------------------------------
January 11, 2000

Douglas Melton, Ph.D.
Dept. of Molecular and Cellular Biology
Harvard University
Howard Hughes Medical Institute
7 Divinity Avenue
Cambridge, MA 02138

Dear Doug:

As part of a legal audit, we recently found that your Scientific Advisory and
Consulting Agreement does not contain an automatic renewal like our other SAB
agreements, but instead contains a five year term ending July 31,1999, with an
option to extend by mutual written agreement.  We have been operating under the
premise that you are still a current member of our Scientific Advisory Board and
would propose to amend your Agreement effective as of August 1, 1994 to add an
automatic renewal clause as follows:

In Section 1, lines 4 and 5, please delete, "provided that the Term may be
extended by mutual written agreement of the parties subject to the prior written
approval of the Institute".  Please add the following at the end of Section 1:
"The Term will be automatically renewed for successive one-year periods, unless
either party gives written notice of no-renewal to the other at least 30 days
prior to the expiration of the initial, or then current renewal term."

All other terms of your Agreement with Ontogeny shall remain in full force and
effect.

If you are in agreement with the above, please sign the enclosed copy of this
letter and send us one copy for our files.  Please call me if you have any
questions or concerns.  We apologize for the oversight and for any
inconvenience.

Very truly yours,

Raul Rodriguez
Senior Vice President, Business Development and Operations

Acknowledged and Agreed,

/s/ Douglas Melton
---------------------------------------
Douglas Melton, Ph.D.

Date:  /s/ 22 Jan.  00
       --------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]